{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:08:43Z","timestamp":1784956123235,"version":"3.55.0"},"reference-count":50,"publisher":"Baishideng Publishing Group Inc.","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Diabetes"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n          <jats:p>Islets of Langerhans beta cells diminish in autoimmune type 1 diabetes mellitus (T1DM). Teplizumab, a humanized anti-CD3 monoclonal antibody, may help T1DM. Its long-term implications on clinical T1DM development, safety, and efficacy are unknown.<\/jats:p>\n          <jats:p>AIM<\/jats:p>\n          <jats:p>To assess the effectiveness and safety of teplizumab as a therapeutic intervention for individuals with T1DM.<\/jats:p>\n          <jats:p>METHODS<\/jats:p>\n          <jats:p>A systematic search was conducted using four electronic databases (PubMed, Embase, Scopus, and Cochrane Library) to select publications published in peer-reviewed journals written in English. The odds ratio (OR) and risk ratio (RR) were calculated, along with their 95%CI. We assessed heterogeneity using Cochrane Q  and I 2 statistics and the appropriate P  value.<\/jats:p>\n          <jats:p>RESULTS<\/jats:p>\n          <jats:p>There were 8 randomized controlled trials (RCTs) in the current meta-analysis with a total of 1908 T1DM patients from diverse age cohorts, with 1361 patients receiving Teplizumab and 547 patients receiving a placebo. Teplizumab was found to have a substantial link with a decrease in insulin consumption, with an OR of 4.13 (95%CI: 1.72 to 9.90). Teplizumab is associated with an improved C-peptide response (OR 2.49; 95%CI: 1.62 to 3.81) and a significant change in Glycated haemoglobin A1c (HbA1c) levels in people with type 1 diabetes [OR 1.75 (95%CI: 1.03 to 2.98)], and it has a RR of 0.71 (95%CI: 0.53 to 0.95).<\/jats:p>\n          <jats:p>CONCLUSION<\/jats:p>\n          <jats:p>In type 1 diabetics, teplizumab decreased insulin consumption, improved C-peptide response, and significantly changed HbA1c levels with negligible side effects. Teplizumab appears to improve glycaemic control and diabetes management with good safety and efficacy.<\/jats:p>","DOI":"10.4239\/wjd.v15.i7.1615","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:50:22Z","timestamp":1720399822000},"page":"1615-1626","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of teplizumab's efficacy and safety in treatment of type 1 diabetes mellitus: A systematic review and meta-analysis"],"prefix":"10.4239","volume":"15","author":[{"given":"Xiao-Lan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Jian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.16"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/mi14010151"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3928\/19382359-20190725-03"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00343"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2018.33.1"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.11.017"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.138"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110708"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020152"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03474-8"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000563"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010390"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003401"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/db20-1185"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v13.i10.835"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-023-00357-y"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012864"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0236"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2753-4"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902226"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-0675"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4786-9"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60931-8"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc8980"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/1524839919893361"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00377-8"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2307\/2533446"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10278-019-00218-y"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-1070-0"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/21925682211003889"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-015-0249-6"},{"key":"B34","doi-asserted-by":"crossref","unstructured":"Szumilas M. Explaining odds ratios. J Can Acad Child Adolesc Psychiatry 2010; 19: 227-229","DOI":"10.1007\/s00787-010-0087-7"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e31817a7ee4"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1037\/1082-989X.11.2.193"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivy163"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4103\/IJPSYM.IJPSYM_193_19"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmni.2020.100795"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26180"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31320-5"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v11.i1.13"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00003.2010"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00743-7"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1517\/14712591003598843"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01847-y"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2174\/1871530320999201209222921"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15237"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03499-0"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00390-4"}],"container-title":["World Journal of Diabetes"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1948-9358\/full\/v15\/i7\/1615.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/1948-9358\/full\/v15\/i7\/1615.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:51:56Z","timestamp":1720399916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1948-9358\/full\/v15\/i7\/1615.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":50,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.4239\/wjd.v15.i7.1615","relation":{},"ISSN":["1948-9358"],"issn-type":[{"value":"1948-9358","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,15]]}}}